We tested VP 16-213 in 16 patients with advanced head and neck cancer after conventional treatments. VP 16-213 was administered orally at the dosage of 100 mg/mq for 5 consecutive days every 3 weeks. No patient achieved an objective response. Toxicity was mild. VP 16-213 given at this dose and schedule revealed no activity in pretreated patients with head and neck cancer.
Get full access to this article
View all access options for this article.
References
1.
FelmanI.E., GrunbergS.M., KiritV.G., OwensJ.C.: Phase II trial of etoposide (VP16) in squamous cell carcinoma of the head and neck.Proceedings ASCO, C631, 1983.
2.
GlickJ.H., TaylorS.G.: Integration of chemotherapy in a combined modality treatment plan for head and neck cancer: A review.Int. J. Rad. Oncol. Biol. Phys., 7: 229–242, 1981.
3.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
